Related Experiment Video
Updated: May 15, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Flow cytometric MRD detection in selected mature B-cell malignancies
Sebastian Böttcher1, Matthias Ritgen, Michael Kneba
1Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany. s.boettcher@med2.uni-kiel.de
Methods in Molecular Biology (Clifton, N.J.)
|January 9, 2013
Summary
Flow cytometry is a key tool for detecting minimal residual disease (MRD) in B-cell malignancies. This study details flow cytometry standardization for accurate MRD detection in chronic lymphocytic leukemia and mantle cell lymphoma.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Minimal residual disease (MRD) quantification post-therapy has prognostic value in mature B-cell malignancies.
- Flow cytometry is increasingly utilized for MRD assessment due to advancements in technology and standardization.
Purpose of the Study:
- To describe general aspects of flow cytometric standardization for MRD detection.
- To detail the application of flow cytometry for MRD detection in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Main Methods:
- Utilizing bench-top cytometers capable of analyzing ≥ 4 colors.
- Implementing improved standardization protocols for flow cytometry.
- Applying flow cytometry for MRD detection in CLL and MCL patient samples.
Main Results:
- Standardized flow cytometry enables accurate quantification of submicroscopic MRD.
- The methodology is applicable to various mature B-cell malignancies, exemplified by CLL and MCL.
- Established protocols enhance the reliability of MRD assessments.
Conclusions:
- Flow cytometry is a valuable and standardized method for MRD detection in B-cell lymphomas.
- Accurate MRD quantification using flow cytometry has independent prognostic significance.
- Standardized flow cytometry protocols are crucial for reliable MRD assessment in clinical practice.
